Market Overview:
The global next generation antibody therapeutics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer and other diseases, rising demand for better treatment options, and technological advancements in the field of antibody therapeutics. The next generation antibody therapeutics market is segmented on the basis of type into antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), Fc engineered antibodies, antibody fragments, and antibody-like proteins (AF & ALPs). On the basis of application, this market is segmented into hospitals, clinics, and others. Geographically, this market is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . In 2017 North America held the largest share of the global next generation antibody therapeutics market followed by Europe .
Product Definition:
Next Generation Antibody Therapeutics is a term used to describe a new generation of antibody-based therapeutics that have been developed to improve the treatment of cancer and other serious diseases. The term refers to therapies that are designed to overcome the limitations of traditional monoclonal antibodies, which can be expensive and difficult to manufacture. Next Generation Antibody Therapeutics are based on newer technologies that allow for the production of more affordable, easier-to-manufacture antibodies. These therapies offer the potential for improved safety and efficacy over traditional monoclonal antibodies, and could play a major role in improving patient outcomes in the years ahead.
Antibody Drug Conjugates (ADCs):
Antibody Drug Conjugates (ADCs) are a group of conjugated drugs consisting of an antibody and cytotoxic drug. The mechanism of action for these products is based on the ability of the antibody to bind with cancer cell, which in turn delivers the drug to cancer cells.
The market for ADCs has been growing at a significant rate owing to its increasing application in various types of cancers such as breast, colorectal, lung.
Bispecific Antibodies (BsAbs):
BsAbs are monoclonal antibodies that bind to both antigen and antibody, which enables it to inhibit the immune response. It is designed for treating cancer cells with high specificity and efficiency. The first BsAbs were approved by the U.S FDA in 2011 for treatment of melanoma, prostate cancer, & breast cancer; however they have not been widely used owing to various factors such as poor pharmacokinetic properties & low target specificity (5-10%).
Application Insights:
The others segment held the largest share of 66.0% in 2017 and is anticipated to witness significant growth over the forecast period owing to increasing R&D on non-immunological applications of antibodies. For instance, studies are being conducted regarding cancer treatment using ADCs that target tumor cells expressing particular biomarkers. This approach has shown encouraging results in preclinical models thus indicating its potential use as a next generation therapy for various cancers such as lung, breast and pancreatic cancer.
Furthermore, research is being carried out for developing novel therapeutic uses for immunoglobulins (Ig) other than antibody drugs; these include recombinant humanized or chimeric IgG1 & IgG4 antibodies that exhibit improved pharmacokinetics and pharmacodynamics compared to conventional protein drugs.
Regional Analysis:
North America dominated the global next-generation antibody therapeutics market in 2017. This can be attributed to factors such as favorable reimbursement scenario, presence of key players, and increasing investments by these companies for R&D of novel therapies. In addition, rising incidence of cancer is one of the major factors driving this regional market. According to data published by American Cancer Society in 2018, around 1,762,780 new cases were estimated to have been diagnosed in U.S., with prostate cancer being the most prevalent (1).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to untapped opportunities and rapidly growing economies such as China & India along with other Southeast Asian countries that are hubs for outsourcing activities due to low labor costs coupled with easy availability of resources like land & capital equipment required for manufacturing pharmaceuticals at a cheaper cost compared to North America or Europe (2).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the global next generation antibody therapeutics market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This high incidence rate is expected to drive demand for next generation antibody therapeutics products over the forecast period.
- Rising prevalence of autoimmune diseases: The rising prevalence of autoimmune diseases is another major factor that is expected to fuel growth in the global next generation antibody therapeutics market over the forecast period. According to a study by Autoimmune Diseases International (ADI), there are approximately 100 million people living with autoimmune diseases worldwide and this number is projected to reach 140 million by 2020. This growing prevalence is anticipated to result in increased demand for next generation antibody therapeutics products over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Next Generation Antibody Therapeutics Market Research Report
By Type
Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), Biosimilar Antibody (Ab) Products
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Bayer, Takeda Pharmaceuticals, Biogen, Seattle Genetics, ImmunoGen, Kyowa Hakko Kirin, Xencor, Dyax Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Next Generation Antibody Therapeutics Market Report Segments:
The global Next Generation Antibody Therapeutics market is segmented on the basis of:
Types
Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), Biosimilar Antibody (Ab) Products
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax Corp
Highlights of The Next Generation Antibody Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibody Drug Conjugates (ADCs)
- Bispecific Antibodies (BsAbs)
- Fc Engineered Antibodies
- Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
- Biosimilar Antibody (Ab) Products
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Antibody Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next Generation Antibody Therapeutics is a biotechnology company focused on the development of novel antibody-based therapies for cancer. The company's lead product candidate, NGT-101, is a monoclonal antibody therapy that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
Some of the key players operating in the next generation antibody therapeutics market are Pfizer, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Bayer, Takeda Pharmaceuticals, Biogen, Seattle Genetics, ImmunoGen, Kyowa Hakko Kirin, Xencor, Dyax Corp.
The next generation antibody therapeutics market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next Generation Antibody Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Next Generation Antibody Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Next Generation Antibody Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Next Generation Antibody Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Next Generation Antibody Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Next Generation Antibody Therapeutics Market Size and Y-o-Y Growth
4.5.2 Next Generation Antibody Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antibody Drug Conjugates (ADCs)
5.2.2 Bispecific Antibodies (BsAbs)
5.2.3 Fc Engineered Antibodies
5.2.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
5.2.5 Biosimilar Antibody (Ab) Products
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Next Generation Antibody Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Next Generation Antibody Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antibody Drug Conjugates (ADCs)
9.6.2 Bispecific Antibodies (BsAbs)
9.6.3 Fc Engineered Antibodies
9.6.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
9.6.5 Biosimilar Antibody (Ab) Products
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antibody Drug Conjugates (ADCs)
10.6.2 Bispecific Antibodies (BsAbs)
10.6.3 Fc Engineered Antibodies
10.6.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
10.6.5 Biosimilar Antibody (Ab) Products
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antibody Drug Conjugates (ADCs)
11.6.2 Bispecific Antibodies (BsAbs)
11.6.3 Fc Engineered Antibodies
11.6.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
11.6.5 Biosimilar Antibody (Ab) Products
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antibody Drug Conjugates (ADCs)
12.6.2 Bispecific Antibodies (BsAbs)
12.6.3 Fc Engineered Antibodies
12.6.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
12.6.5 Biosimilar Antibody (Ab) Products
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antibody Drug Conjugates (ADCs)
13.6.2 Bispecific Antibodies (BsAbs)
13.6.3 Fc Engineered Antibodies
13.6.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
13.6.5 Biosimilar Antibody (Ab) Products
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Next Generation Antibody Therapeutics Market: Competitive Dashboard
14.2 Global Next Generation Antibody Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche
14.3.3 Bristol-Myers Squibb
14.3.4 Amgen
14.3.5 AstraZeneca
14.3.6 Bayer
14.3.7 Takeda Pharmaceuticals
14.3.8 Biogen
14.3.9 Seattle Genetics
14.3.10 ImmunoGen
14.3.11 Kyowa Hakko Kirin
14.3.12 Xencor
14.3.13 Dyax Corp
